Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 6/20 | 0.56 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.54 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.54 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.54 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.54 |
| ▸ | HTR1D | P28221 | 1/20 | 0.54 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.54 |
| ▸ | HTR2B | P41595 | 1/20 | 0.54 |
| ▸ | HTR3A | P46098 | 1/20 | 0.54 |
| ▸ | PDE4A | P27815 | 2/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4052766 | 0.82 | HTR4 (0.77) | HTR4CHRM4CHRM5ADRA2CCHRM3 | |
| SCHEMBL22326357 | 0.78 | SIGMAR1 (0.50) | HTR2B | |
| SCHEMBL738237 | 0.78 | HTR4 (0.53) | HTR4 | |
| SCHEMBL13846068 | 0.77 | HTR4 (0.47) | HTR4CHRM4CHRM5ADRA2CCHRM3 | |
| SCHEMBL3544670 | 0.76 | HTR4 (0.54) | HTR4CHRM4CHRM5ADRA2CCHRM3 | |
| SCHEMBL13175736 | 0.76 | HTR4 (0.54) | HTR4CHRM4CHRM5ADRA2CCHRM3 | |
| SCHEMBL13846090 | 0.76 | HTR4 (0.54) | HTR4CHRM4CHRM5ADRA2CCHRM3 | |
| SCHEMBL15650838 | 0.75 | HSD11B1 (0.56) | HTR4CHRM4CHRM5ADRA2CCHRM3 | |
| SCHEMBL520418 | 0.75 | POLB (0.63) | HSD11B1 | |
| SCHEMBL29531076 | 0.75 | POLB (0.63) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10738016-B2 | BRD4-kinase inhibitors as cancer therapeutics | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2020-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10738016-B2 | BRD4-kinase inhibitors as cancer therapeutics | BRD4, BICRA, BRDT | HTR4 707/4885CHRM4 3146/4885CHRM5 4515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.